A variant in the CHEK2 promoter at a methylation site relieves transcriptional repression and confers reduced risk of lung cancer

Carcinogenesis

Volumn 31, Issue 7, 2010, Pages 1251-1258

  Zhang, Shuyu ^a   Lu, Juan ^a   Zhao, Xueying ^a   Wu, Wenting ^a   Wang, Huibo ^a   Lu, Jun ^b   Wu, Qihan ^c   Chen, Xin ^c   Fan, Weiwei ^a   Chen, Hongyan ^a   Wang, Feng ^a   Hu, Zhibin ^d   Jin, Li ^a   Wei, Qingyi ^e   Shen, Hongbing ^d   Huang, Wei ^f   Lu, Daru ^a  

^a FUDAN UNIVERSITY   (China)

^b FUZHOU GENERAL HOSPITAL   (China)

^c EAST CHINA NORMAL UNIVERSITY   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ANTINEOPLASTIC AGENT; CHECKPOINT KINASE 2; GLYCINE; LUCIFERASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SP1;

ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER GENETICS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CASE CONTROL STUDY; CHILD; CHINESE; CHROMATIN IMMUNOPRECIPITATION; CLINICAL TRIAL; CONTROLLED STUDY; DNA FLANKING REGION; ENZYME ASSAY; EPIGENETICS; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE FREQUENCY; GENE REPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LUNG CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METHYLATION; QUANTITATIVE ANALYSIS; REPORTER GENE; RISK FACTOR; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SURFACE PLASMON RESONANCE; TRANSCRIPTION REGULATION;

ADULT; AGED; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC;

EID: 77954354019     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq089     Document Type: Article

References (44)

1. Parkin,D.M. et al. (2005) Global cancer statistics, 2002. CA Cancer J. Clin., 55, 74-108.
2. Zienolddiny,S. et al. (2006) Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis, 27, 560-567.
3. Hoeijmakers,J.H. (2007) Genome maintenance mechanisms are critical for preventing cancer as well as other aging-associated diseases. Mech. Ageing Dev., 128, 460-462.
4. Bartek,J. et al. (2003) Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell, 3, 421-429.
5. Ahn,J. et al. (2004) The Chk2 protein kinase. DNA Repair (Amst.), 3, 1039-1047.
6. Shiloh,Y. (2003) ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer, 3, 155-168.
7. Chaturvedi,P. et al. (1999) Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene, 18, 4047-4054.
8. Falck,J. et al. (2001) The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature, 410, 842-847.
9. Stevens,C. et al. (2003) Chk2 activates E2F-1 in response to DNA damage. Nat. Cell Biol., 5, 401-409.
10. Yang,S. et al. (2002) PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat. Cell Biol., 4, 865-870.
11. Vaziri,C. et al. (2003) A p53-dependent checkpoint pathway prevents rereplication. Mol. Cell, 11, 997-1008.
12. Bell,D.W. et al. (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science, 286, 2528-2531.
13. Meijers-Heijboer,H. et al. (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(AdvP4C4E74.-1.C3)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat. Genet., 31, 55-59.
14. Vahteristo,P. et al. (2002) A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am. J. Hum. Genet., 71, 432-438.
15. Driver,K.E. et al. (2008) Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population. Carcinogenesis, 29, 333-341.
16. Bahassi el,M. et al. (2007) The breast cancer susceptibility allele CHEK2AdvP4C4E74.-1.C31100delC promotes genomic instability in a knock-in mouse model. Mutat. Res., 616, 201-209.
17. Matsuoka,S. et al. (2001) Reduced expression and impaired kinase activity of a Chk2 mutant identified in human lung cancer. Cancer Res., 61, 5362-5365.
18. Cybulski,C. et al. (2004) CHEK2 is a multiorgan cancer susceptibility gene. Am. J. Hum. Genet., 75, 1131-1135.
19. Dong,X. et al. (2003) Mutations in CHEK2 associated with prostate cancer risk. Am. J. Hum. Genet., 72, 270-280.
20. Lipton,L. et al. (2003) Contribution of the CHEK2 1100delC variant to risk of multiple colorectal adenoma and carcinoma. Cancer Lett., 200, 149-152.
21. Hangaishi,A. et al. (2002) Mutations of Chk2 in primary hematopoietic neoplasms. Blood, 99, 3075-3077.
22. Hofmann,W.K. et al. (2001) Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias. Leuk. Res., 25, 333-338.
23. Miller,C.W. et al. (2002) Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors. Genes Chromosomes Cancer, 33, 17-21.
24. Hu,Z. et al. (2007) Genetic variants in MGMT and risk of lung cancer in Southeastern Chinese: a haplotype-based analysis. Hum. Mutat., 28, 431-440.
25. Grunau,C. et al. (2001) Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res., 29, E65-E5.
26. Su,Y. et al. (1998) Effect of cigarette smoke extract on nitric oxide synthase in pulmonary artery endothelial cells. Am. J. Respir. Cell Mol. Biol., 19, 819-825.
27. Schreiber,E. et al. (1989) Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res., 17, 6419.
28. Henderson,B. et al. (2008) Cigarette smoke is an endothelial stressor and leads to cell cycle arrest. Atherosclerosis, 201, 298-305.
29. Raveendran,M. et al. (2005) Endogenous nitric oxide activation protects against cigarette smoking induced apoptosis in endothelial cells. FEBS Lett., 579, 733-740.
30. Li,R. et al. (1996) Sp1 activates and inhibits transcription from separate elements in the proximal promoter of the human adenine nucleotide translocase 2 (ANT2) gene. J. Biol. Chem., 271, 18925-18930.
31. Walsh,T. et al. (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA, 295, 1379-1388.
32. Kilpivaara,O. et al. (2004) CHEK2 variant I157T may be associated with increased breast cancer risk. Int. J. Cancer, 111, 543-1537.
33. Kleibl,Z. et al. (2009) The CHEK2 gene I157T mutation and other alterations in its proximity increase the risk of sporadic colorectal cancer in the Czech population. Eur. J. Cancer, 45, 618-624.
34. Brennan,P. et al. (2007) Uncommon CHEK2 mis-sense variant and reduced risk of tobacco-related cancers: case control study. Hum. Mol. Genet., 16, 1794-1801.
35. Cybulski,C. et al. (2008) Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers. Carcinogenesis, 29, 762-765.
36. Florescu,A. et al. (2009) Methods for quantification of exposure to cigarette smoking and environmental tobacco smoke: focus on developmental toxicology. Ther. Drug Monit., 31, 14-30.
37. Williams,L.H. et al. (2006) Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers. Clin. Cancer Res., 12, 6967-6972.
38. Zhang,P. et al. (2004) CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer. Mol. Cancer, 3, 14.
39. Wang,H. et al. (2009) Chk2 down-regulation by promoter hypermethylation in human bulk gliomas. Life Sci., 86, 185-191.
40. Kim,D.S. et al. (2009) Epigenetic inactivation of checkpoint kinase 2 gene in non-small cell lung cancer and its relationship with clinicopathological features. Lung Cancer, 65, 247-250.
41. Zaid,A. et al. (2001) Sp1 acts as a repressor of the human adenine nucleotide translocase-2 (ANT2) promoter. Eur. J. Biochem., 268, 5497-5503.
42. Ogra,Y. et al. (2001) Negative regulatory role of Sp1 in metal responsive element-mediated transcriptional activation. J. Biol. Chem., 276, 16534-21659.
43. Won,J. et al. (2002) Opposing regulatory roles of E2F in human telomerase reverse transcriptase (hTERT) gene expression in human tumor and normal somatic cells. FASEB J., 16, 1943-1945.
44. Esteve,P.O. et al. (2007) Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells. J. Biol. Chem., 282, 2615-2625.